First Report of Co‐Inheritance of Hemoglobin British Columbia (HBB:c.304G>A) and β‐Thalassemia IVS‐I‐6 (HBB:c.92+6T>C): Clinical Characterization of an Iranian Case Authors: Kimia Fathalizade, Mahsa Kiani Bigdeli, Seyed Sajad Eghbali, Mohammadtaghi Ghiyasi, Roz Rastgoo, Mohammad Javad Mousavi Published: 2026 ABSTRACT ABSTRACTBackgroundHemoglobin British Columbia is a rare high‐oxygen‐affinity β‐globin variant caused by the HBB:c.304G>A substitution. Its detection is exceptionally uncommon, particularly in the Middle East, and may lead to diagnostic pitfalls when relying solely on hemoglobin separation techniques. Precise molecular characterization is therefore essential for accurate differentiation from other hemoglobinopathies and for expanding knowledge of their regional distribution.Case PresentationWe report a 25‐year‐old asymptomatic Iranian male who was incidentally identified during routine premarital screening due to the presence of an unexpected hemoglobin band. Comprehensive evaluation was performed using capillary zone electrophoresis (CZE), targeted analysis of common α‐globin deletions, full sequencing of the α‐ and β‐globin genes, and long‐range PCR for α‐gene triplications.ResultsCZE revealed a major abnormal hemoglobin fraction (73.2%), with HbA at 21.7% and HbA2 at 5.1%. α‐Globin gene analysis showed no mutations. β‐Globin gene sequencing demonstrated compound heterozygosity for Hb British Columbia (HBB:c.304G>A) and the β‐thalassemia variant IVS‐I‐6 (HBB:c.92+6T>C), a combination not previously reported. Despite the presence of two β‐globin variants, the patient exhibited normal hematologic and biochemical parameters and no clinical symptoms.ConclusionThis is the first documented case of co‐inheritance of Hb British Columbia and the IVS‐I‐6 β‐thalassemia mutation in Iran. The case underscores the crucial role of molecular diagnostics in resolving atypical electrophoretic patterns, preventing misclassification of rare hemoglobin variants, and enriching the understanding of the hemoglobinopathy spectrum in diverse populations. Introduction Hemoglobin (Hb) is a multifunctional heme protein responsible primarily for oxygen transport, but it also contributes to nitric oxide metabolism, acid–base regulation, redox balance, and several catalytic processes essential for cellular homeostasis [1, 2]. Hb consists of a heme group coordinated with a central iron atom and four globin chains encoded by eight developmentally regulated genes. The differential expression of these genes throughout fetal and postnatal life results in distinct hemoglobin tetramers, including HbA1, HbA2, and HbF [3, 4, 5, 6]. Hemoglobinopathies represent one of the most common genetic disorders worldwide, with more than 1000 structural hemoglobin variants and numerous thalassemic defects identified across populations [7]. These disorders arise either from mutations that impair globin‐chain synthesis (thalassemias) or from structural alterations in the globin chains that modify hemoglobin's biochemical and biophysical properties [5, 7]. The prevalence and phenotypic diversity of hemoglobin variants reflect extensive genetic variation influenced by geographical, environmental, and evolutionary factors [8]. Many of these variants alter the oxygen dissociation curve by shifting Hb's oxygen affinity, which can be quantified using p50 measurements and may produce either low‐affinity (high p50) or high‐affinity (low p50) phenotypes [9, 10]. Hemoglobin British Columbia is a rare high‐oxygen‐affinity β‐globin variant characterized by substitution of glutamic acid with lysine at position β101 (G3) [11]. This mutation modifies heme–heme interactions while maintaining a normal Bohr effect and confers biochemical stability comparable to HbA under heat and alcohol denaturation. Electrophoretically, Hb British Columbia migrates between HbA and HbS, often resembling HbC migration patterns, which may complicate laboratory interpretation. Clinically, it is generally benign and is most often associated only with mild erythrocytosis [11]. Reports have primarily originated from individuals of Indigenous or East Indian ancestry, and the variant remains extremely rare globally. Because high‐affinity hemoglobin variants may overlap electrophoretically with more common variants, molecular testing plays an indispensable role in correctly identifying such mutations and preventing diagnostic errors [11]. The IVS‐I‐6 (HBB:c.92+6T>C) mutation is a well‐characterized β‐thalassemia allele that impairs normal mRNA splicing and leads to reduced β‐globin production, frequently manifesting as microcytosis with variable hematologic profiles [11, 12]. In this report, we present, to the best of our knowledge, the first documented case of co‐inheritance of Hb British Columbia (HBB:c.304G>A) and the IVS‐I‐6 β‐thalassemia mutation (HBB:c.92+6T>C) in an Iranian individual. This case highlights the critical role of integrated electrophoretic and molecular analyses in resolving atypical patterns, improving diagnostic accuracy, and expanding the understanding of hemoglobinopathy diversity in the region. Case Presentation Patient Information A 25‐year‐old Iranian man was referred for routine premarital screening. He reported no previous illnesses, medications, or family history of hematologic disorders. He was completely asymptomatic, without fatigue, dyspnea, dizziness, or exercise intolerance. Physical examination revealed no pallor, jaundice, hepatosplenomegaly, or other abnormalities. Initial Laboratory Findings Capillary zone electrophoresis (CZE) demonstrated an abnormal hemoglobin fraction comprising 73.2% of total hemoglobin, alongside HbA at 21.7% and HbA2 at 5.1%. The complete blood count revealed microcytosis and hypochromia (MCV 64.6 fL, MCH 21.5 pg) with normal hemoglobin concentration (16.5 g/dL) (Table 1). TABLE 1Hematological indices and molecular characterization of the proband showing co‐inheritance of Hb British Columbia (HBB:c.304G>A) and β‐thalassemia trait (IVS‐I‐6).Alpha mutation analysisBeta mutation analysisMCV (fl)MCH (pg)HB (g/dL)HbA (%)HbA2 (%)HbF (%)aa/aaIVS‐I‐6, Hb British Columbia variants64.621.516.521.75.173.2 Note: The patient exhibits microcytosis (MCV < 80 fL) and hypochromia (MCH < 27 pg), consistent with the β‐thalassemia trait. The unusually high proportion of the Hb variant (73.2%) compared to HbA (21.7%) is attributed to the reduced output from the β‐thalassemic allele (IVS‐I‐6) in trans to the Hb British Columbia allele.Abbreviations: Hb, hemoglobin; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume. Hematological indices and molecular characterization of the proband showing co‐inheritance of Hb British Columbia (HBB:c.304G>A) and β‐thalassemia trait (IVS‐I‐6). Note: The patient exhibits microcytosis (MCV < 80 fL) and hypochromia (MCH < 27 pg), consistent with the β‐thalassemia trait. The unusually high proportion of the Hb variant (73.2%) compared to HbA (21.7%) is attributed to the reduced output from the β‐thalassemic allele (IVS‐I‐6) in trans to the Hb British Columbia allele. Abbreviations: Hb, hemoglobin; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume. Iron studies (iron and ferritin), liver enzymes, fasting blood glucose, and HbA1c were within normal limits, excluding nutritional deficiency or metabolic causes of the hematologic profile (Table 2). TABLE 2Baseline biochemical, iron metabolism, and glycemic parameters confirming the exclusion of nutritional and metabolic causes of microcytosis.Iron (μmol/L)Ferritin (ng/mL)AST (u/L)ALT (u/L)FBS (mg/dL)HbA1c (%)201202224904.5 Note: Biochemical and metabolic parameters were measured at baseline to exclude nutritional deficiency and systemic causes of microcytosis. All parameters were within normal reference ranges, effectively ruling out iron deficiency (normal serum iron and ferritin), hepatic dysfunction (normal AST, ALT), and diabetes mellitus (normal FBS and HbA1c) as contributing factors to the observed microcytosis or the abnormal electrophoretic pattern. The normal HbA1c level (4.5%) is particularly noteworthy, as high‐affinity hemoglobin variants can sometimes interfere with HbA1c measurement; however, in this case, the value remained reliable and concordant with the normal FBS.Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FBS, fasting blood sugar; Hb, hemoglobin. Baseline biochemical, iron metabolism, and glycemic parameters confirming the exclusion of nutritional and metabolic causes of microcytosis. Note: Biochemical and metabolic parameters were measured at baseline to exclude nutritional deficiency and systemic causes of microcytosis. All parameters were within normal reference ranges, effectively ruling out iron deficiency (normal serum iron and ferritin), hepatic dysfunction (normal AST, ALT), and diabetes mellitus (normal FBS and HbA1c) as contributing factors to the observed microcytosis or the abnormal electrophoretic pattern. The normal HbA1c level (4.5%) is particularly noteworthy, as high‐affinity hemoglobin variants can sometimes interfere with HbA1c measurement; however, in this case, the value remained reliable and concordant with the normal FBS. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; FBS, fasting blood sugar; Hb, hemoglobin. Diagnostic Work‐Up Hematologic and Biochemical Assessment Routine biochemistry and endocrine evaluations were normal. The patient denied symptoms suggesting erythrocytosis, high‐affinity hemoglobin variants, or chronic disease. Molecular and Genomic Testing Genomic DNA was extracted from peripheral blood leukocytes using the salting‐out method. A stepwise molecular evaluation was performed: GAP‐PCR for common α‐globin deletions (−3.7, −4.2, MED, 20.5).Long‐range PCR for α‐globin gene triplication (anti‐3.7).Full Sanger sequencing of the α1 and α2 globin genes.Full Sanger sequencing of the β‐globin (HBB) gene, including intron–exon boundaries. GAP‐PCR for common α‐globin deletions (−3.7, −4.2, MED, 20.5). GAP‐PCR for common α‐globin deletions (−3.7, −4.2, MED, 20.5). Long‐range PCR for α‐globin gene triplication (anti‐3.7). Long‐range PCR for α‐globin gene triplication (anti‐3.7). Full Sanger sequencing of the α1 and α2 globin genes. Full Sanger sequencing of the α1 and α2 globin genes. Full Sanger sequencing of the β‐globin (HBB) gene, including intron–exon boundaries. Full Sanger sequencing of the β‐globin (HBB) gene, including intron–exon boundaries. All assays were carried out at Razi Pathobiology Laboratory (Bushehr) and the Kariminejad–Najmabadi Genetics Center (Tehran), following standard diagnostic protocols. Primer sequences targeting the HBB gene and PCR amplification conditions were selected according to previously published molecular diagnostic protocols for β‐thalassemia and structural hemoglobin variants [13, 14]. The selection of α‐globin deletions tested (−3.7, −4.2, MED, 20.5) was based on their established prevalence in the Iranian population, while the SEA deletion, which is extremely rare in this ethnic group, was not included. Genetic Findings The α‐globin analysis revealed no deletions, point mutations, or triplication (genotype: aa/aa). β‐globin sequencing identified two heterozygous variants: Hemoglobin British Columbia (HBB:c.304G>A)—a structural variant affecting codon 101.IVS‐I‐6 (HBB:c.92+6T>C)—a β‐thalassemia splice‐site mutation. Hemoglobin British Columbia (HBB:c.304G>A)—a structural variant affecting codon 101. Hemoglobin British Columbia (HBB:c.304G>A)—a structural variant affecting codon 101. IVS‐I‐6 (HBB:c.92+6T>C)—a β‐thalassemia splice‐site mutation. IVS‐I‐6 (HBB:c.92+6T>C)—a β‐thalassemia splice‐site mutation. These findings confirmed compound heterozygosity. However, the allelic arrangement (cis vs. trans) could not be determined due to the lack of parental samples. Segregation analysis was therefore recommended to clarify phase and reproductive implications. The electrophoretic and sequencing results corresponding to these findings are shown in Figures 1 and 2, respectively. Capillary zone electrophoresis (CZE) chromatogram of the patient demonstrating the distinct migration pattern of hemoglobin British Columbia. The electropherogram reveals a predominant abnormal hemoglobin peak (73.2%) eluting in zone Z8 (typical for Hb British Columbia), accompanied by a reduced HbA peak (21.7%) and elevated HbA2 (5.1%). The dominance of the variant peak over HbA confirms the compound heterozygous state, where the β‐thalassemia mutation limits the expression of the normal β‐globin chain. Due to partial peak overlap, capillary electrophoresis does not allow precise quantification of the individual hemoglobin fractions; however, relative proportions of HbA and Hb British Columbia remain representative. Molecular confirmation of compound heterozygosity for Hemoglobin British Columbia and IVS‐I‐6 β‐thalassemia by Sanger sequencing. (A) Partial chromatogram of the HBB gene (sense strand) encompassing exon 2. The arrow indicates the position of the c.304G>A transition (codon 101, GAG>AAG), which corresponds to Hemoglobin British Columbia. At this position, the sequencing software displays an ambiguous base call “N” (highlighted), which results from the presence of two superimposed peaks (black G and green A) characteristic of a heterozygous state. This double peak pattern confirms heterozygosity despite the software's inability to assign a single nucleotide. (B) Partial chromatogram showing the IVS‐I‐6 region within intron 1. The arrow indicates the position of the c.92+6T>C splice‐site mutation. Similar to panel A, an “N” is displayed at this position due to the overlapping T (blue) and C (red) peaks, consistent with heterozygosity for this β‐thalassemic allele. Chromatogram visualization and sequence analysis were performed using SnapGene version 8.2.2. Clinical Course and Follow‐Up The patient remained completely asymptomatic, with stable hematologic indices and normal metabolic panel on a 6‐month follow‐up. Reticulocyte counts and iron‐related parameters remained within normal ranges. Given the co‐inheritance of a rare high‐affinity hemoglobin variant and a β‐thalassemia mutation, and considering reproductive implications, genetic counseling was provided. Parental testing and partner screening were recommended to determine phase and to correctly assess future offspring risk. Consent and Ethical Considerations Written informed consent was obtained from the patient for genetic testing and publication of anonymized clinical data, in accordance with the ethical approval granted by the Bushehr University of Medical Sciences. Discussion Hemoglobin disorders comprise a broad spectrum of structural variants and quantitative defects that together affect a substantial portion of the global population and present heterogeneous clinical phenotypes and laboratory profiles [7]. Hemoglobin variants arise from alterations in globin‐chain structure or production, leading to diverse biochemical and electrophoretic behaviors that may complicate diagnosis [6, 15]. Mutations in globin genes that impact Hb are prevalent, affecting around 7% of the global population. Mutations are categorized into two main types: those that hinder the production of globin protein subunits (thalassemias) and those that result in structurally abnormal globin proteins (Hb variants). The latter category usually consists of missense mutations that induce single amino acid substitutions in the globin protein, leading to an aberrant or “variant” hemoglobin tetramer. Although several variants may not induce pathology or anemia and are frequently not categorized as hemoglobinopathies, these mutations are generally characterized as pathological or non‐pathological based on the symptoms they manifest in the affected population, and conventionally, these variations are called after the affected person's place of origin [6]. Most hemoglobin variants are clinically silent; however, some may alter oxygen affinity, electrophoretic mobility, or stability without causing overt symptoms. High‐oxygen‐affinity variants may impair tissue oxygen delivery and stimulate compensatory erythropoiesis, potentially resulting in erythrocytosis [7]. Diagnostic evaluation typically integrates electrophoretic methods with confirmatory molecular testing to accurately classify hemoglobin variants [12]. Hemoglobin British Columbia was first characterized in an East‐Indian individual in Vancouver, British Columbia, Canada, and results from the β101(G3) Glu → Lys substitution, a mutation that alters the tertiary structure of the β‐globin chain and produces a high‐oxygen‐affinity hemoglobin with reduced heme–heme cooperativity and preserved Bohr effect. Functional studies demonstrated that, despite its altered oxygen‐binding properties, the variant retains thermal and chemical stability comparable to HbA, explaining why many heterozygous carriers remain clinically asymptomatic or present only with mild erythrocytosis [16]. Subsequent reports have identified this variant in additional East Indian and Caucasian families, further supporting its overall benign phenotype [17, 18]. In the present case, capillary zone electrophoresis revealed a predominant abnormal peak (73.2%) with reduced HbA (21.7%) and mildly elevated HbA2 (5.1%). This profile is most consistent with a functional scenario in which the Hb British Columbia allele produces structurally abnormal β‐chains while the co‐inherited IVS‐I‐6 allele limits production of normal β‐chains, thereby biasing the circulating β‐chain pool toward the variant form. The markedly high proportion of the variant peak relative to HbA mirrors this mechanistic expectation and concurs with prior observations that reduced expression from a thalassemic allele will amplify the relative representation of a co‐existing structural variant in chromatographic assays. The IVS‐I‐6 (HBB:c.92+6T>C) mutation is a recognized β‐thalassemia allele that affects splicing of the β‐globin pre‐mRNA and commonly results in reduced β‐chain synthesis with variable hematologic consequences, most frequently manifesting as microcytosis with mildly elevated HbA2 in heterozygous carriers. When a structural β‐variant coexists with a β‐thalassemia allele, the resulting hematologic and electrophoretic phenotype reflects the combined effects of altered protein structure and altered quantitative expression, which can obscure routine laboratory interpretation and necessitate molecular clarification [11, 12]. Previous literature further highlights important diagnostic pitfalls associated with this variant. A notable report described a 60‐year‐old woman in whom Hb British Columbia produced a prominent abnormal peak on chromatographic analysis, leading to marked interference with HbA1c quantification and resulting in an erroneously low glycation value that did not correspond with her glycemic profile. This case emphasized the diagnostic pitfall that structurally altered hemoglobins, particularly those eluting outside the HbA0 window, can pose in routine diabetes monitoring and highlighted the need for alternative glycemic assessment methods when unexpected hemoglobin peaks are detected [19]. Our case had fasting blood sugar measured at 90 mg/dL and HbA1c level at 4.5%. Another report documented a pregnant 24‐year‐old woman, who had microcytosis and hypochromia, with a borderline Hb A2 level of 3.9% and an aberrant peak of 32.7% in the Hb C window on HPLC. No β‐thalassemia mutation was detected; however, DNA sequencing revealed the existence of a beta chain variation, Hb British Columbia (HBB: c.304G>A) in the heterozygous condition [11]. Our case's DNA sequencing showed two heterozygote variants of British Columbia Hb (HBB: c.304G>A and HBB:c.92+6T>C). Because Hb British Columbia elutes within the HbC window, misclassification is possible, underscoring the necessity of molecular confirmation when electrophoretic results are discordant [11]. Phenotypic variability among carriers of high‐affinity hemoglobin variants and β‐thalassemia mutations is well recognized and may be influenced by multiple genetic modifiers, including co‐inherited globin defects, regulatory variants affecting globin expression, and differences in erythropoietic response. Isolated heterozygous β‐globin mutations have been reported to produce unexpectedly severe phenotypes resembling β‐thalassemia intermedia, likely due to modifying genetic factors [20, 21]. Conversely, the co‐inheritance of a β‐thalassemia allele with a structural β‐globin variant may attenuate or mask expected features such as erythrocytosis by reducing overall β‐globin production [22, 23, 24]. In the present case, the absence of erythrocytosis despite a high‐affinity hemoglobin variant supports the hypothesis that reduced β‐chain synthesis from the IVS‐I‐6 allele may mitigate the erythrocytotic effect. Nevertheless, as erythrocytosis associated with high‐affinity hemoglobin variants may evolve over time, long‐term clinical follow‐up remains advisable. The present case contributes to this growing body of evidence by documenting that even a high proportion (73.2%) of a high‐affinity variant may not necessarily lead to erythrocytosis when co‐inherited with a β‐thalassemia allele, highlighting the complex genotype–phenotype correlations in hemoglobinopathies. Increased population movement and migration have contributed to the emergence of rare hemoglobin variants in regions where they were previously unreported, posing challenges for screening and prevention programs [25]. In the present case, the patient was of Iranian origin with no history of recent migration, suggesting an indigenous occurrence of this rare combination. To our knowledge, this is the first reported case in Iran documenting the co‐inheritance of Hb British Columbia (HBB:c.304G>A) with the IVS‐I‐6 (HBB:c.92+6T>C) β‐thalassemia allele. Recognition of novel or rare combinations such as this not only enriches regional hemoglobinopathy catalogues but also highlights the continued need for integrated electrophoretic and molecular approaches. Such strategies are essential for preventing misdiagnosis, improving diagnostic precision, and guiding appropriate genetic counseling for individuals and families affected by hemoglobin variants. Conclusion This report describes the first documented co‐inheritance of Hemoglobin British Columbia (HBB:c.304G>A) and the IVS‐I‐6 (HBB:c.92+6T>C) β‐thalassemia allele in Iran. The case illustrates how the interaction between a structural hemoglobin variant and a thalassemic allele can produce an atypical electrophoretic profile, potentially mimicking common hemoglobinopathies. It underscores the indispensable role of molecular diagnostics in accurately characterizing rare hemoglobin variants, preventing analytical pitfalls such as HbA1c interference, and guiding appropriate genetic counseling. Recognition of such rare combinations enriches the molecular epidemiology of hemoglobinopathies and reinforces the need for integrated diagnostic approaches in diverse populations. Author Contributions Kimia Fathalizade and Mahsa Kiani Bigdeli: investigation, writing – original draft preparation. Seyed Sajad Eghbali, Mohammadtaghi Ghiyasi, and Roz Rastgoo: investigation and methodology. Mohammad Javad Mousavi: supervision, conceptualization, methodology, reviewing and editing. Funding The authors have nothing to report. Ethics Statement This study was approved by the Ethics Committee of Bushehr University of Medical Sciences (IR.BPUMS.REC.1403.405). Consent Written informed consent for publication of anonymized clinical and genetic data was obtained from the patient. Conflicts of Interest The authors declare no conflicts of interest.